Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients

Objective: Bevacizumab is the only anti-angiogenic agent approved in first-line therapy for metastatic colorectal cancer (mCRC). Although chemotherapy plus bevacizumab has led to improve outcomes for mCRC patients and is a common choice for first-line treatment of mCRC, previous research has establi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Int J Clin Exp Pathol
Autors principals: Tsai, Hsiang-Lin, Lin, Chih-Hung, Huang, Ching-Wen, Yang, I-Ping, Yeh, Yung-Sung, Hsu, Wen-Hung, Wu, Jeng-Yih, Kuo, Chao-Hung, Tseng, Fan-Ying, Wang, Jaw-Yuan
Format: Artigo
Idioma:Inglês
Publicat: e-Century Publishing Corporation 2015
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4396259/
https://ncbi.nlm.nih.gov/pubmed/25973082
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars